Pfizer to Buy Anacor in $5.2 Billion Deal

Source: Reuters and Bloomberg

May 17, 2016

Pfizer Inc. is buying Anacor Pharmaceuticals Inc. in a $5.2 billion deal to add an eczema gel to its portfolio, reports Reuters.

The deal announcement comes roughly a month after Pfizer scrapped plans to acquire Allergan Plc.

According to Bloomberg, the announced price is a 55 percent premium to Anacor's Friday, May 13, stock price. Before the deal announcement ─ $99.25 per share in cash ─ Anacor shares were down 58 percent from more than $150 last summer.

According to analyst reports, the deal suggests Pfizer making a shift in strengthening its drug portfolio ahead of a decision on selling or spinning off its generic medicines business by late 2016.

Read the full report from Reuters here. 

 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments